Johnson & Johnson
JNJ----
Q2 FY2026 EarningsQ2 FY26 revenue reached $25.31B, up 6.6% YoY and 5.6% operationally. Innovative Medicine grew 7.8% YoY to $16.38B, driven by DARZALEX (+18.9%) and CARVYKTI (+49.4%), despite a 55.2% decline in STELARA due to biosimilar competition. MedTech rose 4.5% YoY to $8.93B, led by Electrophysiology and Shockwave adoption. Net earnings remained flat at $5.53B, with diluted EPS at $2.27. The H1 FY26 net income decline of 34.9% YoY reflects the comparison against a $7.0B one-time talc reserve reversal in H1 FY25.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Johnson & Johnson(JNJ) predict that the Revenue is 25.31 B (+6.6%), Beat estimate;the EBIT is 8.277 B (+3.97%), Miss estimate;the EPS is 2.27 (-0.87%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
25.31B6.60%
25.06B5.55%
+0.25B1.05%
EBITMiss expectations
8.28B3.97%
8.35B4.84%
-0.07B0.87%
EPSMiss expectations
2.270.87%
2.42675.97%
-0.15676.84%
Upcoming earnings report - FY2026 Q3 Earning Release
Available dateOct 13, 2026
Estimate Revenue25.32 B
Estimate EBIT8.842 B
Estimate EPS2.52
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf